NCT03258554 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 63
- group Id
- BG002
- value
- 123
- group Id
- BG003
- value
- 196
- units
- Participants
- groups
- description
- IMRT for seven weeks, 5 fractions/week. Durvalumab 1500 mg IV starts two weeks prior to RT and continues every 4 weeks for a total of seven cycles in the absence of disease progression or unacceptable toxicity.
- id
- BG000
- title
- (Lead-in) RT + Durvalumab
- description
- IMRT for seven weeks, 5 fractions/week. Cetuximab 400 mg/m\^2 IV starts one week prior to RT, then 250 mg/m\^2 weekly for seven additional cycles in the absence of disease progression or unacceptable toxicity.
- id
- BG001
- title
- RT + Cetuximab
- description
- IMRT for seven weeks, 5 fractions/week. Durvalumab 1500 mg IV starts two weeks prior to RT and continues every 4 weeks for a total of seven cycles in the absence of disease progression or unacceptable toxicity.
- id
- BG002
- title
- RT + Durvalumab
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 4
- title
- ≤ 49 years
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 10
- group Id
- BG003
- value
- 19
- title
- 50 - 59 years
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 20
- group Id
- BG002
- value
- 35
- group Id
- BG003
- value
- 61
- title
- 60 - 69 years
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 25
- group Id
- BG002
- value
- 60
- group Id
- BG003
- value
- 88
- title
- 70 - 79 years
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 16
- group Id
- BG003
- value
- 24
- title
- ≥ 80 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 31
- title
- Female
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 54
- group Id
- BG002
- value
- 102
- group Id
- BG003
- value
- 165
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 14
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 56
- group Id
- BG002
- value
- 117
- group Id
- BG003
- value
- 173
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 9
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 2
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 3
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 17
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 50
- group Id
- BG002
- value
- 105
- group Id
- BG003
- value
- 165
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 7
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 28
- group Id
- BG002
- value
- 48
- group Id
- BG003
- value
- 80
- title
- 0
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 27
- group Id
- BG002
- value
- 60
- group Id
- BG003
- value
- 93
- title
- 1
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 15
- group Id
- BG003
- value
- 23
- title
- 2
- description
- 0 - Asymptomatic; 1 - Symptomatic but completely ambulatory; 2 - Symptomatic, \<50% in bed during the day; 3 - Symptomatic, \>50% in bed, but not bedbound; 4 - Bedbound; 5 - Death
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Zubrod performance status
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 24
- group Id
- BG002
- value
- 43
- group Id
- BG003
- value
- 71
- title
- 0 (no comorbidities)
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 39
- group Id
- BG002
- value
- 80
- group Id
- BG003
- value
- 125
- title
- ≥ 1
- description
- An assessment tool used to predict the mortality for a patient who may have a range of concurrent conditions (comorbidities). The score ranges from 0 (no comorbidities) to 35 (highest possible comorbidity load / highest risk of death). For this study, the CCI was modified to exclude the cancer questions: "Has the patient had cancer (other than basal cell skin cancer)?" and "Has the patient had a metastatic solid tumor?".
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Modified Charlson Comorbidity Index (CCI)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 27
- group Id
- BG002
- value
- 55
- group Id
- BG003
- value
- 88
- title
- Oropharynx, p16-positive
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 6
- title
- Unknown, p16-positive
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 15
- group Id
- BG003
- value
- 20
- title
- Oropharynx, p16-negative
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- title
- Unknown, p16-negative
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 10
- title
- Oral cavity
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 13
- group Id
- BG003
- value
- 21
- title
- Hypopharynx
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 30
- group Id
- BG003
- value
- 50
- title
- Larynx
- description
- The biomarker p16 is used as a surrogate marker for human papillomavirus (HPV) infections and is a known prognostic factor in some head and neck cancers.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Primary tumor site and p16 status
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 7
- title
- T0
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 21
- title
- T1
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 16
- group Id
- BG002
- value
- 38
- group Id
- BG003
- value
- 56
- title
- T2
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 20
- group Id
- BG002
- value
- 42
- group Id
- BG003
- value
- 65
- title
- T3
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 15
- group Id
- BG003
- value
- 28
- title
- T4
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 17
- title
- T4a
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 2
- title
- T4b
- description
- Tumor stage per the American Joint Committee on Cancer (AJCC) refers to the size and/or extent of the main tumor. The higher the number after the T, the larger the tumor or the more it has grown into nearby tissues. T's may be further divided to provide more detail, such as T3a and T3b. Lead-in component used 7th edition of AJCC; phase II component used 8th edition.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- T stage, clinical (AJCC 8)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 17
- group Id
- BG003
- value
- 31
- title
- N0
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 28
- group Id
- BG002
- value
- 36
- group Id
- BG003
- value
- 66
- title
- N1
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 29
- title
- N2
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 2
- title
- N2a
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 28
- title
- N2b
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 17
- group Id
- BG003
- value
- 30
- title
- N2c
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 4
- title
- N3
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 2
- title
- N3a
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 4
- title
- N3b
- description
- Regional lymph nodes staging per American Joint Committee on Cancer (AJCC) 7th ed. refers to the number and/or extent of spread of lymph nodes that contain cancer. The higher the number after the N, the greater the involvement of regional lymph nodes. Lead-in component used 7th edition of AJCC; phase II component used 8th edition.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- N stage, clinical (AJCC 8)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 21
- group Id
- BG002
- value
- 35
- group Id
- BG003
- value
- 60
- title
- ≤ 10 pack-years
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 42
- group Id
- BG002
- value
- 88
- group Id
- BG003
- value
- 136
- title
- > 10 pack-years
- description
- A way to measure the amount a person has smoked over a long period of time. It is calculated by multiplying the number of packs of cigarettes smoked per day by the number of years the person has smoked.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Smoking history: pack-years
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 52
- group Id
- BG002
- value
- 104
- group Id
- BG003
- value
- 162
- title
- Absolute or relative contraindication to cisplatin
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 12
- group Id
- BG003
- value
- 17
- title
- Age ≥ 70 with moderate to severe comorbidity or vulnerability to cisplatin
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 17
- title
- Age < 70 with severe comorbidity or vulnerability to cisplatin
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Comorbidity group
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- title
- 1
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 9
- title
- 2
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 10
- group Id
- BG003
- value
- 20
- title
- 3
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 23
- group Id
- BG003
- value
- 37
- title
- 4
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 17
- group Id
- BG002
- value
- 31
- group Id
- BG003
- value
- 50
- title
- 5
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 22
- group Id
- BG002
- value
- 53
- group Id
- BG003
- value
- 79
- title
- ≥ 6
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Number of comorbidity conditions
- unit Of Measure
- Participants
- population Description
- Enrolled participants (i.e. for phase II, randomized)
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 63
- group Id
- BG002
- value
- 123
- group Id
- BG003
- value
- 196
- units
- Participants
- groups
- description
- IMRT for seven weeks, 5 fractions/week. Durvalumab 1500 mg IV starts two weeks prior to RT and continues every 4 weeks for a total of seven cycles in the absence of disease progression or unacceptable toxicity.
- id
- BG000
- title
- (Lead-in) RT + Durvalumab
- description
- IMRT for seven weeks, 5 fractions/week. Cetuximab 400 mg/m\^2 IV starts one week prior to RT, then 250 mg/m\^2 weekly for seven additional cycles in the absence of disease progression or unacceptable toxicity.
- id
- BG001
- title
- RT + Cetuximab
- description
- IMRT for seven weeks, 5 fractions/week. Durvalumab 1500 mg IV starts two weeks prior to RT and continues every 4 weeks for a total of seven cycles in the absence of disease progression or unacceptable toxicity.
- id
- BG002
- title
- RT + Durvalumab
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 4
- title
- ≤ 49 years
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 10
- group Id
- BG003
- value
- 19
- title
- 50 - 59 years
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 20
- group Id
- BG002
- value
- 35
- group Id
- BG003
- value
- 61
- title
- 60 - 69 years
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 25
- group Id
- BG002
- value
- 60
- group Id
- BG003
- value
- 88
- title
- 70 - 79 years
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 16
- group Id
- BG003
- value
- 24
- title
- ≥ 80 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 31
- title
- Female
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 54
- group Id
- BG002
- value
- 102
- group Id
- BG003
- value
- 165
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 14
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 56
- group Id
- BG002
- value
- 117
- group Id
- BG003
- value
- 173
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 9
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 2
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 3
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 17
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 50
- group Id
- BG002
- value
- 105
- group Id
- BG003
- value
- 165
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 7
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 28
- group Id
- BG002
- value
- 48
- group Id
- BG003
- value
- 80
- title
- 0
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 27
- group Id
- BG002
- value
- 60
- group Id
- BG003
- value
- 93
- title
- 1
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 15
- group Id
- BG003
- value
- 23
- title
- 2
- description
- 0 - Asymptomatic; 1 - Symptomatic but completely ambulatory; 2 - Symptomatic, \<50% in bed during the day; 3 - Symptomatic, \>50% in bed, but not bedbound; 4 - Bedbound; 5 - Death
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Zubrod performance status
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 24
- group Id
- BG002
- value
- 43
- group Id
- BG003
- value
- 71
- title
- 0 (no comorbidities)
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 39
- group Id
- BG002
- value
- 80
- group Id
- BG003
- value
- 125
- title
- ≥ 1
- description
- An assessment tool used to predict the mortality for a patient who may have a range of concurrent conditions (comorbidities). The score ranges from 0 (no comorbidities) to 35 (highest possible comorbidity load / highest risk of death). For this study, the CCI was modified to exclude the cancer questions: "Has the patient had cancer (other than basal cell skin cancer)?" and "Has the patient had a metastatic solid tumor?".
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Modified Charlson Comorbidity Index (CCI)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 27
- group Id
- BG002
- value
- 55
- group Id
- BG003
- value
- 88
- title
- Oropharynx, p16-positive
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 6
- title
- Unknown, p16-positive
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 15
- group Id
- BG003
- value
- 20
- title
- Oropharynx, p16-negative
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- title
- Unknown, p16-negative
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 10
- title
- Oral cavity
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 13
- group Id
- BG003
- value
- 21
- title
- Hypopharynx
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 30
- group Id
- BG003
- value
- 50
- title
- Larynx
- description
- The biomarker p16 is used as a surrogate marker for human papillomavirus (HPV) infections and is a known prognostic factor in some head and neck cancers.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Primary tumor site and p16 status
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 7
- title
- T0
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 21
- title
- T1
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 16
- group Id
- BG002
- value
- 38
- group Id
- BG003
- value
- 56
- title
- T2
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 20
- group Id
- BG002
- value
- 42
- group Id
- BG003
- value
- 65
- title
- T3
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 15
- group Id
- BG003
- value
- 28
- title
- T4
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 17
- title
- T4a
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 2
- title
- T4b
- description
- Tumor stage per the American Joint Committee on Cancer (AJCC) refers to the size and/or extent of the main tumor. The higher the number after the T, the larger the tumor or the more it has grown into nearby tissues. T's may be further divided to provide more detail, such as T3a and T3b. Lead-in component used 7th edition of AJCC; phase II component used 8th edition.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- T stage, clinical (AJCC 8)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 17
- group Id
- BG003
- value
- 31
- title
- N0
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 28
- group Id
- BG002
- value
- 36
- group Id
- BG003
- value
- 66
- title
- N1
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 29
- title
- N2
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 2
- title
- N2a
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 28
- title
- N2b
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 17
- group Id
- BG003
- value
- 30
- title
- N2c
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 4
- title
- N3
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 2
- title
- N3a
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 4
- title
- N3b
- description
- Regional lymph nodes staging per American Joint Committee on Cancer (AJCC) 7th ed. refers to the number and/or extent of spread of lymph nodes that contain cancer. The higher the number after the N, the greater the involvement of regional lymph nodes. Lead-in component used 7th edition of AJCC; phase II component used 8th edition.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- N stage, clinical (AJCC 8)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 21
- group Id
- BG002
- value
- 35
- group Id
- BG003
- value
- 60
- title
- ≤ 10 pack-years
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 42
- group Id
- BG002
- value
- 88
- group Id
- BG003
- value
- 136
- title
- > 10 pack-years
- description
- A way to measure the amount a person has smoked over a long period of time. It is calculated by multiplying the number of packs of cigarettes smoked per day by the number of years the person has smoked.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Smoking history: pack-years
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 52
- group Id
- BG002
- value
- 104
- group Id
- BG003
- value
- 162
- title
- Absolute or relative contraindication to cisplatin
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 12
- group Id
- BG003
- value
- 17
- title
- Age ≥ 70 with moderate to severe comorbidity or vulnerability to cisplatin
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 17
- title
- Age < 70 with severe comorbidity or vulnerability to cisplatin
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Comorbidity group
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- title
- 1
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 9
- title
- 2
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 10
- group Id
- BG003
- value
- 20
- title
- 3
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 23
- group Id
- BG003
- value
- 37
- title
- 4
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 17
- group Id
- BG002
- value
- 31
- group Id
- BG003
- value
- 50
- title
- 5
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 22
- group Id
- BG002
- value
- 53
- group Id
- BG003
- value
- 79
- title
- ≥ 6
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Number of comorbidity conditions
- unit Of Measure
- Participants
- population Description
- Enrolled participants (i.e. for phase II, randomized)
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle